Sigba, Mariel S.

HRN: 06-38-15  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/27/2022
CO-AMOXICLAV 625MG (TAB)
09/27/2022
10/04/2022
ORAL
625mg/tab
Q12
T/C Endometritis S/p Nsvd
Waiting Final Action 

Indication:  ProphylaxisEmpiric    Type of Infection:  Reproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: